National Academies Press: OpenBook
« Previous: References
Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

Acronyms

ACOSOG American College of Surgeons Oncology Group
ACRIN American College of Radiology Imaging Network
AE adverse event
ALChEMIST Adjuvant Lung Cancer Enrichment Marker Identification in Sequencing Trial
ALK anaplastic lymphoma kinase
AML acute myeloid leukemia
ASCO American Society of Clinical Oncology
 
BIQSFP Biomarker, Imaging, and Quality of Life Studies Funding Program
BRAF human homolog B of v-raf (Rapidly Accelerated Fibrosarcoma viral oncogene)
 
CALGB Cancer and Leukemia Group B
CCOP Community Clinical Oncology Program
CDER Center for Drug Evaluation and Research
CDMS Common IT Data Management System
CIRB Central Institutional Review Board
CLIA Clinical Laboratory Improvement Amendments
CMS Centers for Medicare & Medicaid Services
CRADA Cooperative Research and Development Agreement
Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
CRUK Cancer Research UK
CSG Clinical Studies Group (in the UK)
CT computed tomography
CTAC Clinical Trials and Translational Research Advisory Group
CTEP Cancer Therapy Evaluation Program
CTU Clinical Trials Unit (in the UK)
 
DNA deoxyribonucleic acid
 
ECOG Eastern Cooperative Oncology Group
EGFR epidermal growth factor receptor
EMA European Medicines Agency
 
FDA Food and Drug Administration
FLT3 fms-like tyrosine kinase 3 (fms is the receptor for macrophage colony stimulating factor)
 
GOG Gynecologic Oncology Group
 
HER2 human epidermal growth factor receptor 2
 
IDE Investigational Device Exemption
IND Investigational New Drug
IOM Institute of Medicine
IP intellectual property
IRB institutional review board
IRF independent radiology facility
IT information technology
 
KRAS Kirsten rat sarcoma oncogene
 
NCCCP NCI Community Cancer Centers Program
NCCTG North Central Cancer Treatment Group
NCI National Cancer Institute
NCORP NCI Community Oncology Research Program
NCPF National Cancer Policy Forum
NCRI National Cancer Research Institute (in the UK)
NCRN National Cancer Research Network (in the UK)
Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
NCTN National Clinical Trial Network
NEWDIGS New Drug Development Paradigms
NGS next-generation sequencing
NHS National Health Service
NIH National Institutes of Health
NIHR National Institute of Health Research (in the UK)
 
OEWG Operational Efficiency Working Group
 
PET positron emission tomography
PFS progression-free survival
PTEN phosphatase and tensin homolog
 
RATIFY Randomized AML Trial In FLT3 in <60 Year olds
RFA request for application
RTOG Radiation Therapy Oncology Group
 
SEMATECH Semiconductor Manufacturing Technology
SOP standard operating procedure
SSC Scientific Steering Committee
START Standard Terms of Agreement for Research Trials
Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

This page intentionally left blank.

Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 79
Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 80
Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 81
Suggested Citation:"Acronyms." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 82
Next: Appendix A: Workshop Statement of Task and Agenda »
Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary Get This Book
×
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The National Clinical Trials Network (NCTN) supported by the National Cancer Institute (NCI) has played an integral role in cancer research and in establishing the standard of care for cancer patients for more than 50 years. Formerly known as the NCI Clinical Trials Cooperative Group Program, the NCTN is comprised of more than 2,100 institutions and 14,000 investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the United States and internationally.

Recognizing the recent transformative advances in cancer research that necessitate modernization in how cancer clinical trials are run, as well as inefficiencies and other challenges impeding the national cancer clinical trials program, the NCI asked the IOM to develop a set of recommendations to improve the federally funded cancer clinical trials system. These recommendations were published in the 2010 report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program.
In early 2011, the NCPF and the American Society of Clinical Oncology (ASCO) held a workshop in which stakeholders discussed the changes they planned to implement in response to the IOM goals and recommendations. Two years later, on February 11-12, 2013, in Washington, DC, the NCPF and ASCO reconvened stakeholders to report on the changes they have made thus far to address the IOM recommendations. At this workshop, representatives from the NCI, the NCTN, comprehensive cancer centers, patient advocacy groups, the Food and Drug Administration (FDA), industry, and other stakeholders highlighted the progress that has been made in achieving the goals for a reinvigorated national cancer clinical trials system. Implementing a National Cancer Clinical Trials System for the 21st Century is a summary of that workshop.
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!